New score could help guide Late-Stage breast cancer treatment decisions

NCT ID NCT01574170

Completed Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to develop and validate a scoring system to identify which patients with metastatic breast cancer are likely to live longer with third-line chemotherapy. Researchers will collect clinical, histological, and biological data from 267 women starting a third line of treatment. The goal is to create a tool that helps doctors and patients make more informed decisions about continuing chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which patients with metastatic breast cancer are most likely to benefit from third-line chemotherapy, avoiding unnecessary treatments.
What could go wrong: This is a prognostic tool study, not a treatment trial. The score may not be accurate enough to change practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER STARTING A THIRD LINE CHEMOTHERAPY

Contacts and locations

Locations

C.M.C.O. Claude Bernard

Albi, 81000, France
CHRU Brest

Brest, 26609, France
CHU Jean Minjoz

Besançon, 25030, France
CHU Rangueil

Toulouse, 31000, France
Centre Eugène Marquis

Rennes, 35042, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Hospitalier Intercommunal de Castres-Mazamet

Castres, 81108, France
Centre Hospitalier Jean Rougier

Cahors, 46005, France
Centre Hospitalier de Rodez

Rodez, 12000, France
Centre Paul Strauss

Strasbourg, 67065, France
Centre d'Oncologie et de Radiothérapie du Parc

Dijon, 21000, France
Clinique La Croix du Sud

Quint-Fonsegrives, 31130, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, 54519, France
Institut de Cancérologie de l'Ouest Paul Papin

Angers, 49933, France
Polyclinique de l'Ormeau

Tarbes, 65000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.